CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells

Cancer immunology research

Volumn 2, Issue 9, 2014, Pages 878-889

  Du, Juan ^a   Lopez Verges, Sandra ^a   Pitcher, Brandelyn N ^a   Johnson, Jeffrey ^a   Jung, Sin Ho ^a   Zhou, Lili ^a   Hsu, Katharine ^a   Czuczman, Myron S ^a   Cheson, Bruce ^a   Kaplan, Lawrence ^a   Lanier, Lewis L ^a   Venstrom, Jeffrey M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD20 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MIDDLE AGED; RECEPTORS, KIR; RITUXIMAB; YOUNG ADULT;

EID: 84964315611     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0158     Document Type: Article

References (0)